Diabetic Retinopathy – Pipeline Review, H2 2012

07:47 EDT 22 Oct 2012 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Diabetic Retinopathy – Pipeline Review, H2 2012 is a new report from Global Markets Direct published on 2012-09-24. This 158-page report is available in PDF from $2000.

Diabetic Retinopathy – Pipeline Review, H2 2012


Global Markets Direct’s, 'Diabetic Retinopathy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Retinopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy. Diabetic Retinopathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Diabetic Retinopathy.
- A review of the Diabetic Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetic Retinopathy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diabetic Retinopathy Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Diabetic Retinopathy 9
Diabetic Retinopathy Therapeutics under Development by Companies 11
Diabetic Retinopathy Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Diabetic Retinopathy Therapeutics – Products under Development by Companies 21
Diabetic Retinopathy Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Diabetic Retinopathy Therapeutics Development 23
Amgen Inc. 23
Quark Pharmaceuticals, Inc. 24
Oxford BioMedica plc 25
RetinaPharma Technologies, Inc. 26
Novagali Pharma SA 27
Antisense Therapeutics Limited 28
Lpath, Inc. 29
BioDiem Ltd 30
ThromboGenics NV 31
R-Tech Ueno, Ltd. 32
Paloma Pharmaceuticals, Inc. 33
Acucela Inc. 34
OcuCure Therapeutics, Inc. 35
ProtAffin Biotechnologie AG 36
Gene Signal International SA. 37
Promedior, Inc. 38
DiaKine Therapeutics, Inc. 39
Inotek Pharmaceuticals Corporation 40
Angstrom Pharmaceuticals, Inc. 41
Sirnaomics, Inc. 42
Resolvyx Pharmaceuticals, Inc 43
Charlesson LLC. 44
Stelic Institute & Co. 45
PanOptica, Inc. 46
Cebix Incorporated 47
Targa Therapeutics Corp. 48
EyeGene, Inc. 49
Ampio Pharmaceuticals, Inc. 50
Diabetic Retinopathy – Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Combination Products 52
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 58
ATL-1103 - Drug Profile 58
sonepcizumab - Drug Profile 59
VCM For Diabetic Retinopathy - Drug Profile 61
ocriplasmin - Drug Profile 62
PARP Inhibitors - Drug Profile 64
SOD Mimetic - Drug Profile 65
Vitreosolve - Drug Profile 66
dexamethasone acetate - Drug Profile 68
DT-23552 - Drug Profile 69
G Family Inhibitor For Diabetic Retinopathy - Drug Profile 70
RX-20001 - Drug Profile 71
OC-10X - Drug Profile 72
Granzyme B/VEGF - Drug Profile 73
A-6 - Drug Profile 74
aganirsen - Drug Profile 75
P-529 Intravitreal/Subconjunctival - Drug Profile 77
adalimumab - Drug Profile 79
doxycycline - Drug Profile 81
Ranibizumab + Laser Photocoagulation - Drug Profile 83
danazol - Drug Profile 85
MTP-131 - Drug Profile 86
bevacizumab - Drug Profile 88
AKB-9778 - Drug Profile 89
BDM-E - Drug Profile 91
RTU-007 - Drug Profile 93
Panretinal Photocoagulation + Ranibizumab - Drug Profile 94
fenofibrate - Drug Profile 95
fenofibrate - Drug Profile 96
PF-04523655 + Lucentis - Drug Profile 97

For more information open Diabetic Retinopathy – Pipeline Review, H2 2012.


Original Article: Diabetic Retinopathy – Pipeline Review, H2 2012


More From BioPortfolio on "Diabetic Retinopathy – Pipeline Review, H2 2012"

Search BioPortfolio:

Relevant Topic

Latest News Clinical Trials Research Drugs Reports Corporate
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...


Searches Linking to this Story